Replimune Group, Inc.
Here’s whether Replimune Group, Inc. (REPL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-8.09% over 10 days); RSI 22 — oversold; weak 1-year return of -71.6%; 3-month momentum negative (-69.2%); rising volume on a downtrend (distribution, 2.41x avg). Currently 83.6% off its 52-week high. Score: -7/7.
REPL is trading below its 200-day MA ($7.35) — a key warning sign the longer-term trend is under pressure. An RSI of 22.0 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -71.6% compares to +35.1% for SPY (trailed the market by 106.7%). The current 83.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.